The post UNI Price Prediction: Oversold Conditions Target $5.85 Recovery by March 2026 appeared on BitcoinEthereumNews.com. Iris Coleman Feb 09, 2026 06:04 The post UNI Price Prediction: Oversold Conditions Target $5.85 Recovery by March 2026 appeared on BitcoinEthereumNews.com. Iris Coleman Feb 09, 2026 06:04

UNI Price Prediction: Oversold Conditions Target $5.85 Recovery by March 2026

2026/02/09 14:20
Okuma süresi: 4 dk


Iris Coleman
Feb 09, 2026 06:04

UNI trades at $3.47 with RSI at 29.32 showing extreme oversold conditions. Technical analysis suggests potential 68% upside to $5.85 resistance zone within 4-6 weeks if support holds.

UNI Price Prediction Summary

• Short-term target (1 week): $3.80-$4.20
• Medium-term forecast (1 month): $5.85-$6.29 range
• Bullish breakout level: $5.34 (Upper Bollinger Band)
• Critical support: $3.04 (Lower Bollinger Band)

What Crypto Analysts Are Saying About Uniswap

While specific analyst predictions from major crypto influencers are limited in recent hours, recent technical analysis from market observers provides valuable insight into UNI’s potential trajectory.

Timothy Morano provided analysis on February 2, 2026, noting that “UNI trades at $3.93 with RSI at 26.78 indicating oversold conditions. Technical analysis suggests potential bounce to $5.74 upper Bollinger Band if key support holds through February.” His target of $5.74 aligns closely with current Bollinger Band resistance levels.

James Ding offered a similar perspective on February 4, 2026, stating “Uniswap (UNI) trades at $3.93 with RSI at 28.36 showing extreme oversold conditions. Technical analysis suggests potential 49-60% upside to $5.85-$6.29 resistance zone within 4-6 weeks if current support holds.” This Uniswap forecast suggests significant recovery potential from current levels.

According to on-chain data from major analytics platforms, oversold conditions in UNI often precede substantial bounces, particularly when RSI drops below 30 as currently observed.

UNI Technical Analysis Breakdown

Uniswap’s technical picture presents a compelling oversold setup at current levels. Trading at $3.47, UNI sits well below all major moving averages, with the 20-day SMA at $4.19 representing immediate resistance and the 200-day SMA at $7.20 highlighting the longer-term bearish trend.

The RSI reading of 29.32 places UNI in deeply oversold territory, similar to conditions that preceded previous significant bounces. The MACD histogram at 0.0000 suggests momentum may be stabilizing, though the overall MACD remains bearish at -0.4862.

Bollinger Bands analysis reveals UNI trading near the lower band at $3.04, with the %B position of 0.1891 indicating proximity to oversold extremes. The upper Bollinger Band at $5.34 represents a key technical target for any meaningful recovery.

Current support levels include immediate support at $3.42 and strong support at $3.37, while resistance appears at $3.54 (intraday high) and $3.60 (strong resistance). The Average True Range of $0.35 suggests moderate volatility in the current environment.

Uniswap Price Targets: Bull vs Bear Case

Bullish Scenario

The bullish case for this UNI price prediction centers on the extreme oversold conditions and historical precedent for bounces from similar RSI levels. If UNI can maintain support above $3.37, the path opens to initial resistance at $3.80 (EMA 12) and subsequently $4.19 (20-day SMA).

A break above $4.19 with volume confirmation could target the $5.34-$5.74 zone, representing the upper Bollinger Band and previous analyst targets. The ultimate bullish target remains the $5.85-$6.29 range identified by recent technical analysis, offering 68-81% upside potential from current levels.

Technical confirmation would require RSI moving above 35-40 and MACD histogram turning positive, suggesting momentum shift from bearish to neutral.

Bearish Scenario

The bearish scenario for Uniswap involves a breakdown below the critical $3.04 lower Bollinger Band support. Such a move could target the $2.50-$2.80 zone, representing significant downside risk.

Key risk factors include broader crypto market weakness, potential regulatory concerns affecting DeFi protocols, and continued institutional selling pressure. A decisive break below $3.37 strong support would likely trigger additional selling toward the $3.04 level.

Should You Buy UNI? Entry Strategy

Current technical conditions suggest a measured approach to UNI accumulation. The oversold RSI reading presents an attractive entry opportunity, but confirmation of support holding is crucial.

Potential entry points include:
– Conservative entry: $3.42-$3.47 range with stop-loss at $3.25
– Aggressive entry: Current levels with wider stop-loss at $2.95
– Confirmation entry: Break above $3.60 with stop-loss at $3.35

Risk management remains paramount given the 50% decline from the 50-day SMA at $5.08. Position sizing should reflect the high volatility environment, with the daily ATR of $0.35 providing guidance for stop-loss placement.

Conclusion

This UNI price prediction suggests significant recovery potential from current oversold levels. The combination of RSI below 30, proximity to Bollinger Band support, and recent analyst targets pointing to $5.85-$6.29 creates a compelling risk-reward setup.

However, successful execution requires confirmation of support holding at $3.37-$3.42 and broader crypto market stability. The medium-term Uniswap forecast remains constructive, with 68% upside potential to $5.85 within 4-6 weeks if technical conditions align.

Disclaimer: Cryptocurrency price predictions involve significant risk and uncertainty. Past performance does not guarantee future results. Always conduct your own research and consider your risk tolerance before making investment decisions.

Image source: Shutterstock

Source: https://blockchain.news/news/20260209-price-prediction-target-uni-oversold-conditions-585-recovery-by-march

Piyasa Fırsatı
UNISWAP Logosu
UNISWAP Fiyatı(UNI)
$3.38
$3.38$3.38
-1.57%
USD
UNISWAP (UNI) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen service@support.mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Paylaş
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Paylaş
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Paylaş
BitcoinEthereumNews2025/09/18 05:26